Our news journalists obtained a quote from the research from the University of Texas, "We hypothesize that the dual myoepithelial/ epithelial composition of ACCs underlie their biological heterogeneity and may impact on their therapeutic management. A recurrent reciprocal translocation of t(6;9)(q22-23; p23-24) resulting in fusion gene partners comprising MYB gene the transcription factor NFIB has been reported in ACC of breast, salivary, lachrymal and ceruminal glands. In fusion positive and a subset of fusion negative ACCs, high expression of the transcript Myb was found. However, the role of Myb protein expression and the potential effect on the downstream targets have not been investigated. To investigate the biological and prognostic significance of use of elevated levels of Myb and its downstream target genes (c-kit, cox-2, bcl-2), we analyzed, by immunohistochemistry, the protein expression of these genes in 156 ACCs. We have found that 55% of ACCs have increased Myb expression mainly confined to myoepithelial cells. We validated Myb expression on a large cohort of ACCs (156 patients). Although no significant effects of the individual Myb and downstream targets c-kit, bcl-2 and cox-2 on survival was noticed, the combinations survival curve for Myb+/c-kit+/cox-2+ showed better survival than combination Myb-/c-kit+/cox-2+."
According to the news editors, the research concluded: "Myb may serve as a new target for the management of this disease, and future therapeutic trials of these tumors may be better based on biomarker stratification and the cellular composition of these tumors."
For more information on this research see: Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biology & Therapy, 2011;12(7):569-73.
The news correspondents report that additional information may be obtained from D. Bell, Dept. of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Keywords for this news article include: Texas, Houston, Genetics, Oncology, Immunology, United States, Cancer Biology, Lymphoid Tissue, Adenoid Cystic Cancer, Adenoid Cystic Carcinoma, Hemic and Immune Systems, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.